Want to see JP:4570 full AI Analyst Report?

Immuno-Biological Laboratories Co., Ltd. (4570) Price & Analysis

0 Followers

4570 Stock Chart & Stats

¥1404.00

¥18.00(3.96%)

At close: Jan 08 4:00 PM EST

¥1404.00

¥18.00(3.96%)

Day’s Range― - ―

52-Week Range¥464.00 - ¥3,820.00

Previous CloseN/A

Volume75.00K

Average Volume (3M)23.51K

Market Cap

¥9.01B

Enterprise Value¥8.09B

Total Cash (Recent Filing)¥989.47M

Total Debt (Recent Filing)¥177.09M

Price to Earnings (P/E)27.4

Beta0.95

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.62%

Share Statistics

EPS (TTM)35.32

Shares Outstanding9,314,590

10 Day Avg. Volume28,690

30 Day Avg. Volume23,506

Financial Highlights & Ratios

PEG Ratio1.18

Price to Book (P/B)6.78

Price to Sales (P/S)12.44

P/FCF Ratio46.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage and rising equity provide financial flexibility and reduce refinancing risk. Improved ROE (~17.8% in 2026) reflects a healthier capital base, enabling the company to fund targeted R&D or incremental commercial expansion without stressing liquidity over the medium term.

High Margins And Profitability RecoveryMargins have recovered to robust levels, indicating strong unit economics and potential pricing power in its assay and reagent lines. Sustained elevated gross and operating margins can support durable free cash flow generation, reinvestment in product development, and improved shareholder returns over multiple quarters.

Consumable, Recurring Revenue ModelA business built on consumable reagents and assay kits creates recurring purchase behavior from labs and clinics, lending stability and predictability to revenues. This structural repeat-revenue profile supports steady cash conversion and reduces dependence on one-off product cycles over the medium term.

Bears Say

Historical Earnings VolatilityThe company swung from deep losses through 2021–2023 to a recent profit recovery, showing earnings sensitivity. That prior volatility implies the turnaround may be fragile; proving sustainable earnings through multiple cycles is needed to reduce structural execution and demand-risk concerns.

Uneven Cash-flow ConsistencyAlthough 2026 cash flows recovered strongly, several prior years had weak or negative operating cash flow and uneven conversion of earnings to cash. This inconsistency raises risk that funding for R&D, working capital or growth initiatives may fluctuate, requiring conservative financial management.

Small Scale And Concentration RiskA small organizational footprint suggests limited commercial scale, narrower product/market diversification, and reliance on a compact management and R&D team. This increases execution risk for scaling sales, broadening product lines, and absorbing adverse demand or regulatory shocks over the medium term.

4570 FAQ

What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?

Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥464.00 and its highest was ¥3820.00 in the past 12 months.

What is Immuno-Biological Laboratories Co., Ltd.’s market cap?

Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥9.01B.

When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?

Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 13 days.

How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?

Immuno-Biological Laboratories Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥8.68 earnings per share for the quarter, beating the consensus estimate of N/A by ¥8.68.

Is Immuno-Biological Laboratories Co., Ltd. overvalued?

According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immuno-Biological Laboratories Co., Ltd. pay dividends?

Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥7.5 which represents an annual dividend yield of 0.62%. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here

What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?

Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?

Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.

What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?

Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥8.68 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.601%.

Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4570

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.